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Abstract
Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, is one of the most
frequently mutated genes in breast cancer, and the mutation status of PIK3CA has clinical relevance related to
response to therapy.
The aim of our study was to investigate the mutation status of PIK3CA gene and to evaluate the concordance between
NGS and SGS for the most important hotspot regions in exon 9 and 20, to investigate additional hotspots outside of these
exons using NGS, and to correlate the PIK3CA mutation status with the clinicopathological characteristics of the cohort.
Methods: In the current study, next-generation sequencing (NGS) and Sanger Sequencing (SGS) was used for the
mutational analysis of PIK3CA in 186 breast carcinomas.
Results: Altogether, 64 tumors had PIK3CA mutations, 55 of these mutations occurred in exons 9 and 20. Out of these 55
mutations, 52 could also be detected by Sanger sequencing resulting in a concordance of 98.4 % between the two
sequencing methods. The three mutations missed by SGS had low variant frequencies below 10 %. Additionally,
4.8 % of the tumors had mutations in exons 1, 4, 7, and 13 of PIK3CA that were not detected by SGS. PIK3CA
mutation status was significantly associated with hormone receptor-positivity, HER2-negativity, tumor grade, and
lymph node involvement. However, there was no statistically significant association between the PIK3CA mutation
status and overall survival.
Conclusions: Based on our study, NGS is recommended as follows: 1) for correctly assessing the mutation status
of PIK3CA in breast cancer, especially for cases with low tumor content, 2) for the detection of subclonal
mutations, and 3) for simultaneous mutation detection in multiple exons.
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Background
Historically, Sanger sequencing (SGS) has been the gold
standard for detecting DNA mutations. However, SGS
has limitations due to its restricted sensitivity and its in-
ability to perform parallel investigation of multiple tar-
gets. Furthermore, somatic cancer mutations can be
difficult to detect using SGS without performing micro-
dissections because tumors are heterogeneous and often
mixed with normal tissue. Recent progress in massive
parallel sequencing, termed next-generation sequencing
(NGS), has increased the speed and efficiency of muta-
tion testing in molecular pathology [1–9]. NGS allows
for the detection of a broad spectrum of mutations, in-
cluding single nucleotide substitutions, small insertions
and deletions, large genomic duplications and deletions,
and rare variations [9].
Targeted NGS, which involves the targeted enrichment
of a set of DNA regions, is used for the parallel sequen-
cing of amplicons derived from multiplex polymerase
chain reaction (PCR) or other amplicon-based* Correspondence: ruza.arsenic@charite.de
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enrichment approaches, such as hybridization capture.
When the amplicon size is kept small (e.g., <175 bp) in
the design of the sequencing panel, NGS is also applicable
to formalin-fixed tissue samples. Moreover, targeted NGS
is more cost efficient than SGS [10]. This high-throughput
technology is currently used with several platforms, in-
cluding the Genome Analyzer/HiSeq/MiSeq (Illumina
Solexa), the SOLiD System (Thermo Fisher Scientific), the
Ion PGM/Ion Proton (Thermo Fisher Scientific), and the
HeliScope Sequencer (Helicos BioSciences) [11, 12].
NGS can be used to detect both somatic and germline
mutations in the cancer genome. The somatic genetic
changes can be classified as either driver or passenger
mutations. The former contribute to tumor development
[13, 14], while the latter do not directly contribute to
tumor development and may be the product of genomic
instability within the tumor. Although SGS and PCR are
routinely used to identify clinically relevant mutations
and select the best treatment for patients, these tech-
niques are insensitive to changes occurring at an allele
frequency lower than 20 %, apart from real-time PCR,
which could reach higher sensitivity [15, 16].
However, the more sensitive and cost-effective multiplex
NGS testing platforms provide comprehensive genomic
information, and thus allow for the implementation of tar-
geted therapies and improved treatment decisions [17].
TP53 and PIK3CA are the most frequently mutated genes
in breast cancer (BC), both being mutated in about one-
third of all primary breast carcinomas [18, 19]. In recent
years, several studies identified the clinical relevance of
PIK3CA mutations in terms of decreasing the benefits of
anti-HER2 therapies and poly-chemotherapies in patients
with PIK3CA mutations [20–22] . In the present study, we
investigated the PIK3CA status of 186 primary BC pa-
tients from the Berlin area using targeted NGS and SGS.
Recent studies have analyzed mutations in hot spots (i.e.,
exon 9 and 20) and only a few studies have analyzed mu-
tations in other exons [23] Consequently, our aims were
to evaluate the concordance between NGS and SGS for
the most important hotspot regions in exon 9 and 20, to
investigate additional hotspots outside of these exons
using NGS, and to correlate the PIK3CA mutation status
with the clinicopathological characteristics of the cohort.
Methods
Patient cohort and histopathological evaluation
Tissue samples were collected from 186 patients with a
diagnosis of primary BC at the Department of Pathology,
University Hospital Charité and the Breast Cancer Center
at the DRK Klinikum Koepenick in Berlin, Germany. The
median follow-up time was 38 months. Data on tumor
histology and tumor grade were evaluated at the time of
primary diagnosis and extracted from pathology reports.
Tumors were graded according to the Bloom-Richardson
grading system modified by Elston and Ellis [24]. HER2
status was determined by immunohistochemistry (IHC)
using the Dako HercepTest kit (Dako, Carpinteria, CA,
USA). Chromatic in situ hybridization (CISH) was also
performed on samples with a HER2 score of 2+. The
estrogen receptor (ER) monoclonal antibody clone SP1
(NeoMarkers, Fremont, CA, USA) was used to identify
the ER status, and the progesterone receptor (PR) sta-
tus was determined with the PR monoclonal antibody
PgR 636 (Dako, Wiesentheid, Germany). Only nuclear
labeling was scored as positive. Negative ER and PR sta-
tus was defined as positivity in <1 % of tumor cells ac-
cording to ASCO/CAP guidelines [25]. HER2 negativity
(HER2-) was defined as the absence of membranous
staining or weak, discontinuous membranous staining.
Cases with moderate membranous staining in >10 % of
the tumor cells were examined by CISH according to
ASCO/CAP guidelines [26]. A proliferation index was
not available for all samples. Representative tumor sam-
ples containing at least 30 % tumor cells were selected
for molecular studies.
Sample cohort and clinical parameters
Median patient age at the time of diagnosis was 65 years,
with a range of 34–95 years.
A total of 149 patients (80.1 %) had ductal carcinoma
and 20 (10.7 %) had lobular carcinoma. Seventeen pa-
tients (9.1 %) had carcinoma of another histological type,
such as mucinous ductal carcinoma with squamous dif-
ferentiation, mixed-ductal and lobular carcinoma, me-
dullary carcinoma, or invasive papillary adenocarcinoma.
None of the patients received any medical treatment re-
lated to BC before surgery. After diagnosis, most (93 %)
of the hormone receptor-positive (HR+) cases were ad-
ministered hormonal therapy alone or in combination
with other therapies according to relevant guidelines.
Ethics approval
Patients provided written informed consent for use of
their biomaterial samples in biomarker studies. Consent
was obtained using the standardized informed consent
forms of the participating institutions. The project and
consent process was approved by the ethics board of the
Charité Hospital, Berlin (reference number EA1/139/05,
last amendment 2013).
DNA extraction, PCR, and PIK3CA semiconductor next-
generation sequencing
Briefly, 10 consecutive 10-μm thick sections were pre-
pared. The first section was stained with hematoxylin/
eosin and the tumor area was marked by a pathologist.
The corresponding area was manually microdissected
from each of the consecutive unstained sections and
transferred to 180 μl of lysis buffer (QIAamp® DNA Mini
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Kit, Qiagen, Venlo, Niederlande) for 10 min at 95 °C.
Enzymatic lysis was carried out with 20 μl of Proteinase
K for 1 h at 56 °C. Subsequent DNA preparation was
performed according to the manufacturer’s instructions,
and the DNA was eluted in 80 μl of elution buffer. Total
nucleic acid concentrations were measured with a Qubit
fluorometer HS DNA Assay (Life Technologies, Carlsbad,
CA, USA) and a TaqMan RNase P Detection Reagents Kit
(Life Technologies). Ten nanograms of genomic DNA
were utilized for the library preparation. The final library
was quantified using an Ion AmpliSeq Library Kit 2.0 (Life
Technologies). The samples were 8-fold multiplexed and
amplified on Ion Spheres Particles using the Ion One-
Touch™ 200 Template Kit v2 DL (Life Technologies).
After library enrichment and quality control on a Qubit
instrument (Ion Sphere Quality Control Kit, Life Tech-
nologies), the samples were sequenced using the Ion 318
chip v2 according to the standard protocol of the chip
manufacturer.
A customized sequencing panel consisting of 154
amplicons from 48 genes was designed using the Ion
AmpliSeq Designer to cover the most frequent somatic
mutations found in BC. The panel included six ampli-
cons located in PIK3CA exons 1, 4, 7, 9, 13, and 20. The
genomic positions and primer sequences can be found
in the well plate data sheet generated by the Ion Ampli-
Seq Designer (Additional file 1: Table S1). Only samples
with at least 30 % tumor cells within the dissected area
were included in the study.
Base calling and alignment to the human genome
(hg19) were executed with the Torrent Suite Software
4.0.3. The mean coverages (minimum – maximum) of
the amplicons were 4128 bp (1315–22668 bp) for
exon 1, 5237 bp (1962–25371 bp) for exon 4,
2044 bp (347–12066 bp) for exon 7, 3588 bp (278–
20808 bp) for exon 9, 3742 bp (1386–20063 bp) for
exon 13, and 1552 bp (438–9901 bp) for exon 20.
Variant calling was executed using the Torrent Vari-
ant Caller 4.2 and the low stringency somatic variant
calling protocol. Only non-synonymous nucleotide ex-
changes were considered for the analysis of single nu-
cleotide polymorphisms.
Sanger sequencing primers and sequencing parameters
Primers were designed using the Primer Design Tool
from NCBI. The primers were as follows:
exon 9 forward 5´-
GGGAAAAATATGACAAAGAAAGC-3´,
exon 9 reverse 5´-GAGATCAGCCAAATTCAGTT-3´,
exon 20 part 1 forward 5´-
CATTTGCTCCAAACTGACCA-3´,
exon 20 part 1 reverse 5´-
TgTgCATCATTCATTTgTTTCA-3´,
exon 20 part 2 forward 5´-
TTGATGACATTGCATACATTCG-3´,
and exon 20 part 2 reverse 5´-
GGTCTTTGCCTGCTGAGAGT-3´.
The sequencing reactions were loaded on the 3730xl
DNA Analyzer from Hitachi (Applied Biosystems). Se-
quence traces from tumor DNA samples were aligned to
the genomic reference sequence and analyzed using Seq-
Pilot software (Applied Biosystems).
Statistical evaluation
Statistical analyses were conducted using the SPSS 19
statistical software (SPSS Inc., Chicago, IL, USA) and the
statistical language R (Foundation for Statistical Comput-
ing, Vienna, Austria). Significance of associations between
PIK3CA status and age, ER/PR status, tumor stage, and
histological grade were assessed using a Fisher’s exact test,
a chi-squared test, and a chi-squared test for trends. Over-
all survival was analyzed using the Kaplan-Meier method
and the log-rank test. All tests were two-tailed, and results
were considered significant when p < 0.05. Barplots and
beeswarm plots were produced using the R package
graphics and beeswarm [27, 28].
Results
Prevalence of different types of PIK3CA mutations using
NGS
Using NGS to sequence the PIK3CA gene in each of the
186 tissue samples identified a total of 64 tumors with
exon mutations (34.4 %), which agreed with the 36 %
PIK3CA mutation rate in BC reported by the Cancer
Genome Atlas (TCGA) [18, 19]. As shown in Fig. 1, the
mutations were distributed as follows: exon 20 (34 cases;
18.3 %), exon 9 (19 cases; 10.2 %), and other exons (1, 4,
7, or 13) (9 cases; 4.8 %). In very few samples (2 cases;
1.1 %), we found mutations in two exons. The majority
of mutations were base pair substitutions (60 cases,
93.8 %). Additionally, we detected deletions (4 cases,
6.3 %). Sixty of the tumors (93.7 %) had a single muta-
tion in the PIK3CA gene, while three tumors had two
mutations in the PIK3CA gene. The most frequent mu-
tations were p.H1047R (31 cases, 48.4 %), p.E545K (11
cases, 17.2 %), and p.E542K (6 cases, 9.4 %) (Table 1).
Three mutations, p.N347T, p.G451_D454del, and
p.L456V, were not described in any of the studies reported
in COSMIC (http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic), TCGA [18, 19], or any other large gen-
omic database [29, 30]. Thus, they are being described
for the first time in our study. Additionally, a single nu-
cleotide polymorphism (rs3729674) (NC_000003.11:g.
178917005A >G) was found in 33 cases. Out of a total of
55 mutations in exons 9 and 20 that were detected using
NGS, 49 were also detected by SGS. By resequencing
Arsenic et al. BMC Clinical Pathology  (2015) 15:20 Page 3 of 9
discrepant cases using SGS, we found an additional
three cases with mutations with small peak heights that
could be detected by analyzing the electropherograms
manually. A comparison of the NGS and SGS results is
shown in Fig. 2. The three mutations in exon 9 and
exon 20 that were missed by SGS had low variant fre-
quencies of 4 % (twice) and 7 %.
PIK3CA mutations and clinical characteristics
PIK3CA mutations were analyzed for correlation with
several clinicopathological parameters at the time of
the diagnosis: age, tumor size, tumor grade, nodal sta-
tus, HR status, HER2 expression, and histological sub-
type (Table 2). PIK3CA mutations were most frequently
found in HR+, HER2- (p = 0.002), and well-differentiated
(G1; p < 0.001) cases (Fig. 3a and b). Furthermore, there
was a statistically significant difference between cases with
different nodal statuses; there were more cases with
PIK3CA mutations in the N1 group (p = 0.042). We found
no statistically significant correlation between mutation
status and age, tumor size, or histological tumor type.
When we compared mutations in the other exons (1,
4, 7, and 13) with the clinicopathological parameters, we
found a trend toward enrichment of the mutations in
lower grade tumors, but this trend did not reach statis-
tical significance (p = 0.104). There was no statistically
significant difference between PIK3CA mutation status
in these other exons and cases that were HR+, HR-,
HER2+, or HER2-. Also, we could not detect differences
in nodal status, tumor size, or age.
An overall survival analysis was performed on 184 pa-
tients with available follow-up data. In this group, no
statistically significant association was found between
long-term survival and the PIK3CA mutation status
Fig. 1 PIK3CA mutations in breast cancer: frequency of mutations, including information on the affected exons
Table 1 Hotspots of PIK3CA mutations in breast cancer
Exon Mutation Number Frequency (%) Total number
1 R108del, R109del 1, 2 1.6, 3.1 3
4 N345K, N347T (new), D350N 3,1,1 4.7, 1.6, 1.6 5
7 G451_D454del (new), p.L456V (new) 1,1 1.6, 1.6 2
9 E542K, E545K, Q546K, Q546R 6, 11, 1, 1 9.4, 17.2 19
13 E726K 2 3,1 2
20 D1029H, N1044K, H1047L, H1047R, G1049R 1, 1, 3, 31, 1 1.6, 1.6, 48.4, 4.7, 1.6 37
total: 68
Using semiconductor NGS, we identified a total of 68 non-silent mutations in 186 breast cancer samples (34.4 %). The most frequent aberrations were p.H1047R,
p.E545K, and p.E542K
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(Fig. 4a). There was also no difference in overall survival
related to the mutational status of different PIK3CA
exons (Fig. 4b).
Discussion
The precise identification of genomic alterations is cru-
cial for personalized cancer therapy. Molecular testing
for mutations in cancer susceptibility genes is mainly
performed using SGS of individual exons after PCR. The
detection threshold of SGS requires an allele frequency
of approximately 20 % [31], but BC tissue is heteroge-
neous, consisting of tumor, stromal, and inflammatory
cells, leading to a varying proportion of tumor cells ran-
ging from 20-95 % [32]. Therefore, we speculated that a
significant proportion of PIK3CA mutations are missed
by SGS. There are studies available from other organ
systems, including the lung, which report a higher detec-
tion rate of mutations using NGS rather than SGS [33,
34]. In general, the detection sensitivity of NGS reported
in previous studies ranges from 94–99.9 % [35–39], which
is above the sensitivity of Sanger Sequencing. Accord-
ingly, the aim of the present study was to use NGS for
the analysis of PIK3CA mutations to determine whether
additional changes could be identified that might lead
to better correlation of the clinicopathological charac-
teristics of breast tumors with PIK3CA mutations. We
also sought to evaluate the prognostic significance of
PIK3CA mutation status as previously reported by sev-
eral authors [40–44]. To this end, we compared the
performance of NGS and SGS in the same cohort of pa-
tients, and identified PIK3CA mutations in 34.4 % of
breast tumors using NGS, which is in agreement with
the mutation rate reported in TCGA [45].
Overall, we were able to report a good degree of con-
cordance between the two sequencing methods. Only
three mutations that were detected by NGS could not be
found by SGS due to low variant frequencies below
10 %. Nevertheless, this finding indicates that NGS is
more sensitive than SGS, particularly for the detection
of low frequency mutations. This has also been reported
in previous studies. Rohlin et al. [46] showed that Sanger-
based sequencing techniques have problems picking out
“minority” gene sequences (mutations below 15 %). Mean-
while, Walsch et al. performed a study on 300 high-risk
BC families that screened for mutations in hotspots, and
found previously undetected changes in 52 probands [47].
These results clearly support the use of targeted sequen-
cing because it is more sensitive than SGS when it comes
to identifying low frequency mutations. Our study, which
is the first to compare NGS and SGS for sequencing the
PIK3CA gene in BC, adds support for this viewpoint. Add-
itionally, the results of our study showed that ~5 % of the
mutations were in other exons, and the best and most
cost-effective method for detecting these mutations was to
use parallel sequencing or targeted NGS. Due to the low
mutation rate in these other exons (1, 4, 7, and 13) and a
lack of statistical significance when correlated with clini-
copathological data, we abstained from validating these
mutations by SGS. The clinical relevance of PIK3CA mu-
tations outside exon 9 and 20 should be further investi-
gated in future studies.
The PIK3CA mutations detected by NGS in our study
clustered in two previously reported “hotspot” regions in
exons 9 and 20, with most of the mutations clustering in
exon 20, which is in agreement with the SGS results re-
ported in our previous study [48]. The consequences of
Fig. 2 Detection sensitivity of semiconductor NGS compared to Sanger sequencing. a Barplot showing the number of mutations detected by
both Sanger sequencing and NGS and the mutations detected only by NGS. b Beeswarm plot showing the variant frequencies of the mutations
detected only by NGS and those detected by both methods
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each mutation on the function and regulation of PIK3CA
requires further consideration. The three novel mutation
detected in our study are located in the C2 domain of the
PIK3CA gene. The C2 is often involved in phospholipid
membrane binding, consequently it is possible that these
mutations lead to increased membrane binding, as exten-
sively discussed in the study by Ikenoue at al. [49]. In the
study by Gymnopoulos at al, the authors showed that the
mutants in C2 domain increase basic positive surface
charge of that domain and may therefore mediate im-
proved recruitment of p110α to the cell membrane,
making lipid kinase activity independent of signals trans-
mitted through the regulatory subunit, p85 [50]. One of
these three mutations, p.L456V is predicted to be prob-
ably damaging with a score of 0.988 (sensitivity: 0.27;
specificity: 0.99) when analyzed with polyPhen-2 pre-
diction programe.
The goal of our previous study was to analyse only
exon 9 and 20 mutations, hence we could not detect
these three mutations in this study.
We also noted the presence of multiple mutations in
four cases, which has not been reported previously. The
significance of these double mutants is unknown, but it
is possible that these tumors are multiclonal, and a sec-
ond hit was required to provide a selective growth ad-
vantage if the first mutation was a less potent activator
of the kinase.
We found that PIK3CA was most frequently mutated
in cases that were HR+ and HER2-, which agrees with
previously published data [51, 52]. We found signifi-
cantly more PIK3CA mutations in G1 tumors suggesting
that theses mutations occur early in BC development,
which has also been shown in other studies [53]. Add-
itionally, PIK3CA mutations were highly correlated with
lymph node status (N+), which is one of the clinical
markers associated with patient survival and response to
therapy [54, 55]. The finding that PIK3CA mutations are
more commonly found in HR+ tumors may point to dif-
ferences in pathogenesis and disease progression between
HR+ and HR- tumors. Furthermore, the correlation be-
tween PIK3CA mutations and lymph node metastasis sug-
gests that activation of the PI3K/Akt pathway may
increase the invasion of cancer cells into the lymph nodes.
This is supported by the fact that PIP3 regulates cell
mobility [56].
There is controversy regarding the prognostic signifi-
cance of PIK3CA mutations. Cizkova et al. [57] described
more favorable metastasis-free survival in patients with
PIK3CA mutations, but Jensen et al. [22] and Baselga et
al. [58] reported reduced survival rates and worse out-
comes. The largest published study evaluated the PIK3CA
genotype in 687 tumor samples from patients enrolled in
a prospective phase III clinical trial. Those with PIK3CA
mutations had a better prognosis for the first three
years compared to those carrying wild type PIK3CA al-
leles, but this difference disappeared with a longer
follow-up [59,60]. In our study, there was no significant
association between PIK3CA mutational status and overall
survival, indicating that an activated PIK3CA pathway
alone is not a prognostic factor for BC.
An interesting finding by Fu at al. showed that
PIK3CA-activating mutations are associated with better
outcomes in ER+ patients receiving endocrine therapy
[61]. This agrees with the observation that PIK3CA muta-
tions are more frequent in luminal A tumors compared
Table 2 Correlation of PIK3CA mutation status with the
clinicopathological characteristics of breast cancer
Clinicopathological parameters Mutated (%) Wild type (%) P
All Tumor Cases 64 (34.4) 122 (65.6) NS
Histological Type NS
Ductal/Other Carcinoma 53 (32.5) 110 (67.5)
Lobular Carcinoma 11 (47.8) 12 (52.2)
Tumor Stage NS
T1 13 (30.2) 28 (65.1)
T2 37 (34.9) 69 (65.1)
T3 9 (42.9) 12 (57.1)
T4 5 (41.7) 7 (58.3)
Node Status 0.042
N0 25 (27.8) 65 (72.2)
N+ 37 (42.5) 50 (57.5)
Tumor Grade <0.001
G1 16 (80.0) 4 (20.0)
G2 35 (36.5) 61 (63.5)
G3 13 (18.8) 56 (81.2)
Hormone Receptor Status 0.002
HR+ 58 (40.3) 86 (59.7)
HR- 6 (14.3) 36 (85.7)
HER2 Status 0.032
HER2+ 3 (13.6) 19 (86.4)
HER2- 61 (37.2) 103 (62.8)
Age NS
<50 years 6 (26.1) 17 (73.9)
>50 years 58 (35.6) 105 (64.4)
Molecular Type 0.003
HR+/HER2- 57 (42.5) 77 (57.5)
HR+/HER2+ 1 (10.0) 9 (90.0)
HR-/HER2+ 2 (16.7) 10 (83.3)
HR-/HER2- 4 (13.3) 26 (86.7)
The mutation frequency, as determined by NGS, decreased with increasing
tumor grade: 85 % for G1, 37 % for G2, and 20 % for G3. PIK3CA mutations
were more frequently detected (42 %) in HR+ breast cancer than in HR- breast
cancer (14 %). PIK3CA mutations were more frequently detected in HER2-
breast cancer (38 %) than in HER2+ breast cancer (14 %)
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with luminal B tumors (e.g., 45 % vs. 29 % in the TCGA
cohort) [45]. In contrast, in HER2+ BC, several reports
show that PIK3CA mutations predict adverse outcomes
after treatment with trastuzumab [20, 21]. As such, the
impact of PIK3CA mutations on the clinical outcome of
BC seems to vary with the background of other genomic
alterations such as HER2 status.
PIK3CA mutations also appear to have a significant
interest in the prediction of response to targeted therap-
ies, as many drugs specifically targeting PI3K or other
effectors of the PI3K/AKT pathway are intended to be
administered only to patients with tumor bearing a mu-
tation of PIK3CA, which makes the somatic mutations
detection more and more important [62].
In summary, our results show that NGS is more sensi-
tive than SGS for detecting PIK3CA mutations in BC
samples, and that PIK3CA mutations are significantly re-
lated to HR and HER2 expression status and tumor
grade. Further studies are needed to systematically ex-
plore the functional relevance of PIK3CA mutations and
the contribution of PIK3CA mediated activation of the
downstream and upstream signaling pathways in breast
tumor development and progression.
Conclusions
1. This is the first paper in which NGS and SGS were
compared sequencing PIK3CA gene in breast cancer.
Fig. 3 Strong association of PIK3CA status with molecular subtype and tumor grade in breast cancer. a PIK3CA mutations were more frequent in
HR+/HER2- breast cancer (40 %) compared with the other subtypes (11 %-20 %). b The mutation frequency decreased with increasing tumor
grade: 80 % in G1, 36 % in G2, and 19 % in G3
Fig. 4 Correlation of overall survival with the PIK3CA mutation status in breast cancer. a Kaplan-Meier analysis comparing patients with mutated
PIK3CA (green line) and wild type PIK3CA (blue line) did not reveal a statistically significant difference in survival. b Kaplan-Meier analysis of the
PIK3CA mutation status stratified for the affected exon did not reveal a statistically significant difference in survival, but there was a trend toward
better survival for the cases with a mutation in exon 9. Exon 9 mutation (p = 0.39) vs. exon 20 mutation (p = 0.41) vs. other exon mutations (p = 0.16)
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2. We found overall a good concordance between the
two methods (98,4 %), but better sensitivity of NGS
when it comes to identifying low frequency
mutations(<10 %).
3. PIK3CA mutation status in breast cancer correlated
strongly with HR+ and HER2-, and N1 + .
Additional file
Additional file 1: Table S1. Genomic positions and the primer
sequences. (XLS 45 kb)
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